Rocket Pharmaceuticals (RCKT) Equity Average (2016 - 2025)
Historic Equity Average for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $333.9 million.
- Rocket Pharmaceuticals' Equity Average fell 651.25% to $333.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $333.9 million, marking a year-over-year decrease of 651.25%. This contributed to the annual value of $477.9 million for FY2024, which is 269.3% down from last year.
- Rocket Pharmaceuticals' Equity Average amounted to $333.9 million in Q3 2025, which was down 651.25% from $383.2 million recorded in Q2 2025.
- Over the past 5 years, Rocket Pharmaceuticals' Equity Average peaked at $516.8 million during Q4 2023, and registered a low of $333.9 million during Q3 2025.
- For the 5-year period, Rocket Pharmaceuticals' Equity Average averaged around $434.8 million, with its median value being $436.2 million (2022).
- In the last 5 years, Rocket Pharmaceuticals' Equity Average soared by 9181.04% in 2021 and then plummeted by 2432.59% in 2024.
- Rocket Pharmaceuticals' Equity Average (Quarter) stood at $470.2 million in 2021, then decreased by 8.87% to $428.5 million in 2022, then rose by 20.61% to $516.8 million in 2023, then fell by 23.28% to $396.5 million in 2024, then dropped by 15.78% to $333.9 million in 2025.
- Its Equity Average was $333.9 million in Q3 2025, compared to $383.2 million in Q2 2025 and $437.7 million in Q1 2025.